AstraZeneca, a major pharmaceutical company, has sued Utah’s Attorney General Derek Brown over a recently passed state law ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Camizestrant will reach blockbuster status in 2030 with total sales worth $1.1 billion, according to GlobalData’s analyst ...

AstraZeneca (LSE: AZN) has received European approval for a fixed-duration regimen of Calquence (acalabrutinib) in ...

Drugmaker AstraZeneca said on Friday that it had received approval from the European Commission for fixed-duration regimens ...

The AstraZeneca PLC ADR AZN rose 1.64% to $73.00 Wednesday, on what proved to be an all-around mixed trading session for the ...

AstraZeneca PLC closed 19.58% short of its 52-week high of £133.88, which the company reached on September 3rd.

AstraZeneca Plc and Daiichi Sankyo Co.’s Enhertu delayed the advance of a common type of breast cancer by more than a year in ...

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

Quarterly Net Profit at Rs. 58.25 crore in March 2025 up 47.55% from Rs. 39.48 crore in March 2024. EBITDA stands at Rs. 102.52 crore in March 2025 up 76.61% from Rs. 58.05 crore in March 2024.

AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...